Reliance Global Group (EZRA) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
23 Jan, 2026Company overview and business model
Operates as a diversified insurance company focused on acquiring and managing wholesale and retail insurance agencies, with a strong emphasis on InsurTech platforms and digital transformation.
Growth strategy centers on aggressive M&A, targeting undervalued agencies in growing or underserved segments, and expanding operations nationally.
Proprietary platforms 5MinuteInsure.com (B2C) and RELI Exchange (B2B) leverage AI and data mining to streamline insurance quoting and sales, now active in 46 states with over 30 carriers.
Recent initiatives include a digital asset treasury strategy and the formation of EZRA International Group to invest in high-tech sectors, especially in Israel.
Financial performance and metrics
FY 2024 commission income was $14.1M, up 2% year-over-year, with a net loss of $9.1M, a 24% improvement from the prior year.
Adjusted EBITDA (AEBITDA) for 2024 was $(321K), a 39% improvement from 2023.
As of September 30, 2025, cash and restricted cash totaled $3.5M, with working capital of $1.6M and stockholders’ equity of $6.7M.
Nine months ended September 30, 2025: commission income declined 8.7% year-over-year, primarily due to asset sales; net loss was $5.6M.
Significant asset sales in 2025 generated $6.05M in cash and enabled repayment of $5.5M in long-term debt.
Use of proceeds and capital allocation
Net proceeds of approximately $5.3M from the offering are intended for general corporate purposes, including working capital, growth initiatives, acquisitions, digital asset purchases, marketing, debt repayment, and potential investments.
Management has broad discretion over use of funds; no definitive acquisition agreements are in place as of the filing.
Latest events from Reliance Global Group
- Net loss improved to $1.4M as insurance growth and tech/life sciences investments advanced.EZRA
Q1 20268 May 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026 - Revenue up 2%, net loss down 24%, and tech advances set stage for further growth.EZRA
Q4 202426 Dec 2025